Expression of Iron-Related Proteins Differentiate Non-Cancerous and Cancerous Breast Tumors
Authors:
- Sara PizzamiglioSPSara Pizzamiglio
- Maida De BortoliMBMaida De Bortoli
- Elena TavernaETElena Taverna
- Michele SignoreMSMichele Signore
- Silvia VeneroniSVSilvia Veneroni
- William Chi-Shing ChoWilliam Chi-Shing Cho
- Rosaria OrlandiRORosaria Orlandi
- Paolo VerderioPVPaolo Verderio
- Italia BongarzoneIBItalia Bongarzone
Open Access
- 14 February 2017
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 18 (2) , 410
Abstract
We have previously reported hepcidin and ferritin increases in the plasma of breast cancer patients, but not in patients with benign breast disease. We hypothesized that these differences in systemic iron homeostasis may reflect alterations in different iron-related proteins also play a key biochemical and regulatory role in breast cancer. Thus, here we explored the expression of a bundle of molecules involved in both iron homeostasis and tumorigenesis in tissue samples. Enzyme-linked immunosorbent assay (ELISA) or reverse-phase protein array (RPPA), were used to measure the expression of 20 proteins linked to iron processes in 24 non-cancerous, and 56 cancerous, breast tumors. We found that cancerous tissues had higher level of hepcidin than benign lesions (p = 0.012). The univariate analysis of RPPA data highlighted the following seven proteins differentially expressed between non-cancerous and cancerous breast tissue: signal transducer and transcriptional activator 5 (STAT5), signal transducer and activator of transcription 3 (STAT3), bone morphogenetic protein 6 (BMP6), cluster of differentiation 74 (CD74), transferrin receptor (TFRC), inhibin alpha (INHA), and STAT5_pY694. These findings were confirmed for STAT5, STAT3, BMP6, CD74 and INHA when adjusting for age. The multivariate statistical analysis indicated an iron-related 10-protein panel effective in separating non-cancerous from cancerous lesions including STAT5, STAT5_pY694, myeloid differentiation factor 88 (MYD88), CD74, iron exporter ferroportin (FPN), high mobility group box 1 (HMGB1), STAT3_pS727, TFRC, ferritin heavy chain (FTH), and ferritin light chain (FTL). Our results showed an association between some iron-related proteins and the type of tumor tissue, which may provide insight in strategies for using iron chelators to treat breast cancer.Keywords
This publication has 34 references indexed in Scilit:
- Intracellular Iron Chelation Modulates the Macrophage Iron Phenotype with Consequences on Tumor ProgressionPLOS ONE, 2016
- Local iron homeostasis in the breast ductal carcinoma microenvironmentBMC Cancer, 2016
- Iron homeostasis in host defence and inflammationNature Reviews Immunology, 2015
- Hepcidin - A novel biomarker with changing trendsPharmacognosy Reviews, 2015
- Hepcidin and ferritin blood level as noninvasive tools for predicting breast cancerAnnals of Oncology, 2013
- The significance of ferritin in cancer: Anti-oxidation, inflammation and tumorigenesisBiochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2013
- Validation of tumor‐associated macrophage ferritin light chain as a prognostic biomarker in node‐negative breast cancer tumors: A multicentric 2004 national PHRC studyInternational Journal of Cancer, 2011
- The iron metabolism of neoplastic cells: alterations that facilitate proliferation?Critical Reviews in Oncology/Hematology, 2002
- Serum ferritin concentration in early breast cancerBritish Journal of Cancer, 1976
- Measurement of Serum Ferritin by Radioimmunoassay: Results in Normal Individuals and Patients With Breast Cancer 2JNCI: Journal of the National Cancer Institute, 1975